USA - NASDAQ:EPRX - CA29842P1053 - Common Stock
EPRX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. EPRX has a great financial health rating, but its profitability evaluates not so good. EPRX does not seem to be growing, but still is valued expensively.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -122.72% | ||
ROE | -128.38% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | 159.94 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 8.72 | ||
Quick Ratio | 8.72 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
NASDAQ:EPRX (10/21/2025, 10:01:04 AM)
5.75
-0.13 (-2.21%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | N/A | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 12.9 | ||
P/tB | 12.9 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -122.72% | ||
ROE | -128.38% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 252.94% | ||
Cap/Sales | N/A | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 8.72 | ||
Quick Ratio | 8.72 | ||
Altman-Z | 159.94 |